Columnist Robin Stemple knows that his physical challenges aren't his fault, but that doesn't make it any easier to avoid feeling ashamed.

Permanent; Fitzroy location; Challenging and rewarding work environment; About the Role An opportunity is available for a Grade 3 Physiotherapist to join the ...

In a March 10 update, Leede analyst Douglas Loe maintained a “Speculative Buy” rating and US$16.00 target on Satellos Bioscience ...

Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional ...

Regenxbio Inc. RGNX shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202. • Regenxbio stock is among today’s weakest ...

Solid Biosciences (SLDB) stock dips after new Phase 1/2 trial data for SGT-003, its gene therapy for Duchenne muscular dystrophy. Read more here, ...

SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in ...

US biotech major Biogen has presented additional results from the Phase Ib study of salanersen, an investigational novel ...

The Toronto Beaches Children's Youth Chorus is shown in concert in this submitted photo. By NATASHA JACKSON The Toronto Beaches Children’s Youth Chorus ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy.

Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases.

Regenxbio said ​on Wednesday ‌that an ​interim ​data from a ⁠early-to-mid ​stage ​study of its experimental ​gene ​therapy in patients with ‌Duchenne ⁠muscular dystrophy showed continued ​improvement ...